Effectiveness of Cingal™ for Improving Pain Scores and Function in Anterior Knee Pain

Launched by BANFF SPORT MEDICINE FOUNDATION · Jan 26, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called Cingal™ for people suffering from anterior knee pain, a common condition that causes discomfort at the front of the knee. Cingal™ is designed to improve knee function and provide relief from pain by combining a lubricant (hyaluronic acid) and a steroid (triamcinolone). The goal of the study is to see if this treatment can help those who have not found relief from other treatments like physical therapy or medication.

To participate in this trial, individuals must be between 18 and 35 years old and have been experiencing knee pain for at least two months. They should have a diagnosis of anterior knee pain that hasn't improved despite trying conservative treatments for at least six weeks. It's important to note that certain conditions, such as previous knee injuries or surgeries, may prevent someone from participating. If eligible, participants can expect to receive the Cingal™ treatment and will be monitored for changes in their pain and knee function. This trial is currently not recruiting, but it represents an important step in finding effective treatments for knee pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 - 35 years
• • Standard weight-bearing AP and skyline view knee x-rays
• • Retropatellar or peripatellar knee pain for a minimum of 2 months
• • Confirmed diagnosis of AKP that has failed to improve with a minimum of 6 weeks of conservative treatment (activity modification, supervised physiotherapy, exercise therapy, taping or bracing, NSAIDS)
• • Pain aggravated by at least two of the following patellofemoral joint loading activities: squatting, running, ascending or descending stairs, or sitting with prolonged knee flexion.
• Exclusion Criteria:
• • X-ray evidence of knee osteoarthritis or fracture
• • Meniscal or ligamentous injury assessed or suspected on clinical examination
• • Previous knee surgery
• • History of patellar instability
• • Any contraindication to knee injection (overlying skin condition, joint infection, significant joint effusion, coagulopathy, previous adverse reaction, etc.)
• • Known allergy to Cingal™ or its constituents
• • Previous knee injection within the last 3 months
• • BMI greater than 30 kg/m2
• • Diabetes, inflammatory conditions (rheumatologic disease, ankylosing spondylitis), or concurrent medical conditions which may result in chronic pain or altered pain sensation
• • Pregnant or breastfeeding
• • Workers Compensation Board case
• • Patient involved in litigation